UNSPSC 51172165: Darifenacin hydrobromide

This classification denotes an antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CR02EYQ8GV. European Medicines Agency schedules Darifenacin hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21464. Darifenacin hydrobromide generally arises in the molecular formula C28H31BRN2O2. The term 'darifenacin hydrobromide' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule darifenacin hydrobromide under HS 29349990 and SITC 51579.

As of Q4 2014, DARIFENACIN HYDROBROMIDE remains US FDA's Preferred Term for this commodity. Darifenacin hydrobromide bears US NLM NCI C78068. SMILES: C1CCC(CC1)C(C2CCCCC2)([C@@H]3CCN(C3)CCC4CCC5C(C4)CCO5)C(=O)N.BR.

UNSPSC 51172165 Darifenacin hydrobromide is a Commodity code that captures individual pharmaceutical products—in this case, a specific anticholinergic medication—procured by state and local health and human services agencies, corrections departments, and cooperative purchasing alliances to support clinical operations, pharmacy benefit programs, and institutional healthcare delivery. State and local governments buy this product as part of broader pharmaceutical supply contracts, formulary programs, and drug-testing or specimen-collection initiatives rather than as a standalone line item. The issuing bodies include state health and human services commissions (pursuing direct-to-manufacturer pharmacy initiatives and multi-state cooperative purchasing), county corrections departments managing offender drug-testing programs, and multi-state cooperative purchasing alliances aggregating demand across multiple jurisdictions and member agencies.

Recent activity centers on Texas and Minnesota. The Texas Health and Human Services Commission posted RFI HHS0017013 (due April 3, 2026) exploring direct-to-manufacturer prescription capabilities, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026 and contract commencement July 1, 2026. A third opportunity—Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug-testing services (due July 23, 2026, estimated award August 10, 2026, contract value $600,000)—frames pharmaceutical testing within a larger service scope spanning lab certification, electronic result reporting, and alternative testing methodologies. The MMCAP procurement, structured through authorized wholesalers AmerisourceBergen (Cencora), Cardinal Health 110 and 112, and Morris & Dickson, applies to participating state and local facilities across Minnesota and Oregon, with pricing evaluation weighted 75 percent and administrative compliance 25 percent; vendors must maintain cGMP and Drug Supply Chain Security Act certification and carry $5,000,000 commercial general liability coverage.